胸壁推量对乳腺癌重建并发症及局部控制的影响
该回顾性队列纳入1997至2016年746例接受乳房切除、重建及PMRT的乳腺癌患者,比较接受与未接受胸壁推量(CWB)者的重建并发症和局部失败率。中位随访5.2年,多因素分析显示CWB与感染、皮肤坏死及假体外露显著相关,假体失败风险独立增加,且未带来局部控制获益,即使在高危亚组中亦然。
要点
- CWB与感染、皮肤坏死和假体外露显著相关。
- 假体重建患者中CWB独立增加假体失败风险。
- CWB未改善局部控制,高危亚组亦无获益。
核心结论
- 乳房切除术后放疗中省略胸壁推量可改善乳房重建结局而不损害局部肿瘤控制。
研究设计与样本
- 回顾性病历审查纳入746例1997至2016年在本机构接受乳房切除、乳房重建及PMRT的乳腺癌患者。
- 按是否接受胸壁推量(CWB)分组,比较重建并发症及局部失败累积发生率。
主要发现
- 中位随访5.2年,379例(51%)接受CWB,367例(49%)未接受,多数临床病理特征组间均衡。
- 多因素分析显示CWB与感染、皮肤坏死及假体外露显著相关。
- 假体重建患者中,CWB独立增加假体失败风险。
- CWB与局部肿瘤控制获益无关,即使在高危亚组中亦无关联。
临床怎么用
- 在乳房切除术后放疗中可考虑省略胸壁推量,以改善重建结局且不损害局部控制。
局限性
- 本研究为单机构回顾性病历审查,非随机设置。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Giving an additional radiation dose to the incision or chest wall has been a practice, but it has never been studied in a randomized setting, and it might lead to inferior cosmetic outcomes. This study aims to evaluate whether delivery of a chest wall boost (CWB) to the mastectomy scar or chest wall is independently associated with reconstruction complications and to assess its disease control efficacy in the setting of breast reconstruction. METHODS AND MATERIALS: We conducted a retrospective chart review of 746 patients with breast cancer who underwent mastectomy, breast reconstruction, and PMRT; all underwent treatment at our institution during 1997 to 2016. Various reconstruction techniques were used among this cohort including autologous reconstruction, single-stage direct-to-implant reconstruction, and 2-stage tissue expander implant. Cohorts were divided by administration of CWB. The primary objective was comparing the rate of reconstruction complications including skin necrosis, fat necrosis and infection between groups. Subgroup analysis for patients with implant-based reconstruction was performed to evaluate the effect of CWB on implant-related complications such as capsular contracture, implant exposure, and implant failure. The secondary objective was comparison of the cumulative incidence of local failure between groups overall and within clinically high-risk subgroups. RESULTS: The median follow-up was 5.2 years. Most clinicopathologic features were well balanced between the 379 (51%) patients who received CWB and the 367 (49%) who did not. On multivariate analysis, CWB was significantly associated with infection, skin necrosis, and implant exposure. For implant reconstruction patients, CWB independently increased risks of implant failure. CWB administration was not associated with local tumor control benefits, even in high-risk subgroups. CONCLUSIONS: Our findings suggest that omission of chest wall boost in postmastectomy radiation improves breast reconstruction outcomes without compromising local tumor control.
引用
- Naoum GE, Salama L, Ho A, et al. The Impact of Chest Wall Boost on Reconstruction Complications and Local Control in Patients Treated for Breast Cancer. Int J Radiat Oncol Biol Phys. 2019. PMID: 31055108. doi:10.1016/j.ijrobp.2019.04.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。